Medigene’s T-cell-focused immunotherapies have the potential to treat a wide range of cancers in various stages, the company claims.

Its strategy is to advance its proprietary clinical development programs, beginning with the field of hematological malignancies, and to offer further development options, including solid tumors, to selected partners.